News for hackers. Stuff that matters.
Re:‘Pharmacy of the developing world’ under attack from the ... by pen2l on Tuesday August 25, 2015 @02:49PM (#10118695)
Science is hard, making these drugs is hard. It's after years and years, decades even, of research that we determine what might work as a drug... whether it is safe or not, double-checking, triple-checking its efficacy after it has been made, etc. etc.

To do this it costs lab space, it costs machines that easily go in the millions, it costs sweat and tears of scientists, it takes the lives of many generations of scientists sometimes. The stakes are already high for those who take on these projects. Already, we have a problem with PhDs in the health sciences field making shit money. You want to further discourage them into going in this field by denying them what little they get now? So that they rather make easy money serving you ads based on the information they've gotten from observing your habits?

Re:‘Pharmacy of the developing world’ under attack from the ... by emodendroket on Tuesday August 25, 2015 @03:33PM (#10118954)
Come on. The scientists are not seeing the lion's share of the money from sky-high drug prices (and besides that, you can see some plainly opportunistic moves like recategorizing drugs to raise the fees that don't have anything whatsoever to do with new research).
Re:‘Pharmacy of the developing world’ under attack from the ... by pinaceae on Tuesday August 25, 2015 @03:50PM (#10119036)
scientist/founders do, see practically all bio-tech startups.

exactly the same as in tech - founders reap the big rewards, individual coders less so.

Re:‘Pharmacy of the developing world’ under attack from the ... by pen2l on Thursday August 27, 2015 @04:16AM (#10128182)
In my circle of friends at least, PhDs working on various technologies had their names on patents. When big companies bought these patents, they actually received good money. Not retirement money of course, but a few good tens of thousands.
Re:‘Pharmacy of the developing world’ under attack from the ... by mercurial on Tuesday August 25, 2015 @04:04PM (#10119105)
How many of these cancer drugs are made by bio-tech startups, exactly?
Re:‘Pharmacy of the developing world’ under attack from the ... by danielweber on Tuesday August 25, 2015 @05:58PM (#10119723)
These don't break it down by "start-up" but:

http://pipeline.corante.com/archives/2010/11/04/where_drugs_...

58% from pharmaceutical companies.

18% from biotech companies..

16% from universities, transferred to biotech.

8% from universities, transferred to pharma.

Pharma and biotech companies do develop some drugs themselves, but the majority model is for a start-up to form around a single drug, and if it looks promising a big player buys them up to finish testing and then market it. If the drug looks promising the company is killed.

Venture capital is basically doing the job of drug discovery.

Re:‘Pharmacy of the developing world’ under attack from the ... by mercurial on Tuesday August 25, 2015 @04:22PM (#10119185)
Assuming your premise regarding low salaries is correct (I have no idea), the choice between a small set of people making better money and a much larger group not dying is, morally speaking, fairly straightforward.

But I suspect the reality is different. I can imagine a couple of reasons for low salaries: Big Pharma would like nothing more than pay its personnel decently, but they're barely breaking even. Alternatively, the ratio between PhDs and jobs available doesn't work in the favour of PhDs. In which case, Big Pharma making even more money would translate into additional mansions for C-level executives, not better salaries for PhDs.

Which explanation do you feel is the most likely?